Celltrion today announced that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is approved ...

Korea's pharmaceutical giant Celltrion said Monday that it has received approval from Canadian health authorities for a ...

South Korean biopharmaceutical firm Celltrion announced Thursday that its third plant in Songdo, Incheon, has officially ...

Biopharmaceutical company Celltrion said Thursday that it began the commercial operation of its third plant for drug ...

South Korea's antitrust regulator on Tuesday said it has fined leading drugmaker Celltrion 435 million won ($309,900) for ...

South Korean biopharmaceutical firm Celltrion said Monday that it has received approval from Health Canada for Omlyclo, its omalizumab biosimilar referencing Xolair, designed to treat allergic asthma ...

Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat ...

Pharmaceutical and biotech businesses were enthusiastic about the UPC before the court opened, but so far there has only been ...

Celltrion's asthma treatment Omlyclo, a biosimilar of Novartis's Xolair, has received Canadian approval for chronic urticaria, rhinosinusitis, and allergic asthma ...

The drugmaker will use the new facility as a pipeline for existing and new product manufacturing, including biosimilars ...

SEOUL, Nov. 27 (Yonhap) -- South Korean drugmaker Celltrion Inc. plans to achieve annual sales of 5 trillion won (US$3.58 ...